Global Restless Leg Syndrome Market, By Type (Primary Restless Legs Syndrome and Secondary Restless Legs Syndrome), Therapy Type (Pharmacological Therapies and Non-pharmacological Therapies), Treatment Type (Medication and Surgery), Drugs (Dopaminergic Agents, Anti-seizure Agent, Benzodiazepines, Opioids and Others), Route of Administration (Oral and Injectable), End Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights of Restless Leg Syndrome Market
Data Bridge Market Research analyses that the restless leg syndrome will exhibit a CAGR of around 6.70% for the forecast period of 2021-2028. Growing demand for targeted mode of therapies, surge in the research and development activities for the development of novel drugs and therapies, high unmet need of treatment and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of restless leg syndrome market.
Also known as Willis Ekbom disease, restless leg syndrome is a neurological disease that creates an overwhelming need to continuously move the legs by creating a throbbing sensation in them. The condition is on its worst when a person is sitting or lying down. Restless leg syndrome is a result of combination of both genetic and environmental factors.
Growing prevalence of neurological disorders globally is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure and upsurge in the strategic collaboration rate among the market players are other factors also fostering the growth of the market. Increasing personal disposable income coupled with rising prevalence of genetic diseases is other indirect determinant that will create lucrative market growth opportunities.
However, rising introduction of generic drugs and unfavourable reimbursement scenario will pose a major challenge to the market growth. Also, high costs associated with research and development proficiencies coupled with dearth of skilled professionals will further derail the market growth rate. Patent expiration of branded drugs will also hamper the market growth rate.
This restless leg syndrome market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on restless leg syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Restless Leg Syndrome Market Scope and Market Size
The restless leg syndrome market is segmented on the basis of type, therapy type, treatment type, drugs, route of administration and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the restless leg syndrome market is segmented into primary restless legs syndrome and secondary restless legs syndrome.
- On the basis of therapy type, the restless leg syndrome market is segmented into pharmacological therapies and non-pharmacological therapies.
- On the basis of treatment type, the restless leg syndrome market is segmented into medication and surgery.
- On the basis of drugs, the restless leg syndrome market is segmented into dopaminergic agents, anti-seizure agent, benzodiazepines, opioids and others. Dopaminergic agents segment is sub-segmented into pramipexole, ropinirole and rotigotine. Anti-seizure agent segment is sub-segmented into gabapentin. Benzodiazepines segment is sub-segmented into clonazepam. Opioids segment is sub-segmented into codeine and propoxyphene.
- On the basis of route of administration, the restless leg syndrome market is segmented into oral and injectable.
- On the basis of end users, the restless leg syndrome market is segmented into hospitals, home care, speciality clinics and others.
Restless Leg Syndrome Market Country Level Analysis
The restless leg syndrome market is analysed and market size insights and trends are provided by country, type, therapy type, treatment type, drugs, route of administration and end users as referenced above.
The countries covered in the restless leg syndrome market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the restless leg syndrome market owing to the rising affordability of drugs and surge in the awareness about the availability of treatment options. Asia-Pacific is projected to score highest growth rate and exhibit the CAGR for the forecast period. This is because of the rising expenditure to develop healthcare infrastructure and growing prevalence of neurological disorders.
The country section of the restless leg syndrome market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The restless leg syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Restless Leg Syndrome Market Share Analysis
The restless leg syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to restless leg syndrome market.
The major players covered in the restless leg syndrome market report are GlaxoSmithKline plc, Ligand Pharmaceuticals Incorporated, Jazz Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc., Intas Pharmaceuticals Ltd, Serina Therapeutics, Apotex Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Glenmark Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Endo Pharmaceuticals Inc., Novartis AG, Aurobindo Pharma, Zydus Cadila, Dr. Reddy’s Laboratories Ltd, Alembic Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd, Unichem Laboratories and Boehringer Ingelheim International GmbH among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-